计算溶液所需的质量、体积或浓度。
活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
---|
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
P126755-10mg |
10mg |
现货 ![]() |
| |
P126755-25mg |
25mg |
现货 ![]() |
| |
P126755-50mg |
50mg |
现货 ![]() |
| |
P126755-100mg |
100mg |
现货 ![]() |
|
英文别名 | 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine | NNACHAUCXXVJSP-UHFFFAOYSA-N | Pitolisant | DB11642 | NSC-523123 | BDBM50247053 | N07XX11 | Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]- | Q426044 | Wakix (TN) | BCP13114 | SCHEMBL117648 | DTXSID3 |
---|---|
规格或纯度 | Moligand™, ≥98% |
英文名称 | Pitolisant |
生化机理 | 说明:IC50 值:0.16 nM(Ki 值);1.5 nM(EC50)[1]Pitolisant(BF2.649)是重组人 H3 受体的一种新型、强效、选择性非咪唑类反向激动剂。BF2.649 是一种竞争性拮抗剂,Ki 值为 0.16 nM,同时也是一种反向激动剂,EC50 值为 1.5 nM,其内在活性比环丙沙星高出约 50%。体外:BF2.649 是一种竞争性拮抗剂,Ki 值为 0.16 nM,是一种反向激动剂,EC50 值为 1.5 nM,内在活性比环丙西凡高出约 50%。Pitolisant 在啮齿动物受体上的体外效力约低 6 倍[1]。体内:在小鼠体内,口服生物利用系数(即口服和静注后曲线下血浆面积之比)为 84%。BF2.649 剂量依赖性地提高了小鼠大脑中的远甲基组胺水平,远甲基组胺是组胺能神经元的一个指标。 |
运输条件 | 常规运输 |
作用类型 | 拮抗剂 |
作用机制 | 组胺 H3 受体反向激动剂 |
产品介绍 |
Pitolisant(BF2.649;Ciproxidine)是新型的人重组H3受体选择性反向激动剂,Ki为0.16 nM。 Pitolisant (BF2.649) is a novel, potent, and selective nonimidazole inverse agonist at the recombinant human H3 receptor (Ki=0.16 nM). |
ALogP | 4.3 |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
---|
PubChem SID | 504765139 |
---|---|
分子类型 | 小分子 |
IUPAC Name | 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine |
INCHI | InChI=1S/C17H26ClNO/c18-17-9-7-16(8-10-17)6-4-14-20-15-5-13-19-11-2-1-3-12-19/h7-10H,1-6,11-15H2 |
InChi Key | NNACHAUCXXVJSP-UHFFFAOYSA-N |
Canonical SMILES | C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl |
Isomeric SMILES | C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl |
PubChem CID | 9948102 |
分子量 | 295.85 |
溶解性 | DMSO |
---|---|
分子量 | 295.800 g/mol |
XLogP3 | 4.300 |
氢键供体数Hydrogen Bond Donor Count | 0 |
氢键受体数Hydrogen Bond Acceptor Count | 2 |
可旋转键计数Rotatable Bond Count | 8 |
精确质量Exact Mass | 295.17 Da |
单同位素质量Monoisotopic Mass | 295.17 Da |
拓扑极表面积Topological Polar Surface Area | 12.500 Ų |
重原子数Heavy Atom Count | 20 |
形式电荷Formal Charge | 0 |
复杂度Complexity | 235.000 |
同位素原子数Isotope Atom Count | 0 |
定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
所有立体化学键的总数The total count of all stereochemical bonds | 0 |
共价键合单元计数Covalently-Bonded Unit Count | 1 |
1. Ligneau X, Perrin D, Landais L, Camelin JC, Calmels TP, Berrebi-Bertrand I, Lecomte JM, Parmentier R, Anaclet C, Lin JS et al.. (2007) BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology.. J Pharmacol Exp Ther, 320 (1): (365-75). [PMID:17005916] [10.1021/op500134e] |
2. Lin JS, Dauvilliers Y, Arnulf I, Bastuji H, Anaclet C, Parmentier R, Kocher L, Yanagisawa M, Lehert P, Ligneau X et al.. (2008) An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients.. Neurobiol Dis, 30 (1): (74-83). [PMID:18295497] [10.1021/op500134e] |
3. Celanire S, Wijtmans M, Talaga P, Leurs R, de Esch IJ. (2005) Keynote review: histamine H3 receptor antagonists reach out for the clinic.. Drug Discov Today, 10 (23-24): (1613-27). [PMID:16376822] [10.1021/op500134e] |
4. Stocking EM, Letavic MA. (2008) Histamine H3 antagonists as wake-promoting and pro-cognitive agents.. Curr Top Med Chem, 8 (11): (988-1002). [PMID:18673168] [10.1021/op500134e] |
5. Pierson PD, Fettes A, Freichel C, Gatti-McArthur S, Hertel C, Huwyler J, Mohr P, Nakagawa T, Nettekoven M, Plancher JM et al.. (2009) 5-hydroxyindole-2-carboxylic acid amides: novel histamine-3 receptor inverse agonists for the treatment of obesity.. J Med Chem, 52 (13): (3855-68). [PMID:19456097] [10.1021/op500134e] |
6. Ligneau X, Landais L, Perrin D, Piriou J, Uguen M, Denis E, Robert P, Parmentier R, Anaclet C, Lin JS et al.. (2007) Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649.. Biochem Pharmacol, 73 (8): (1215-24). [PMID:17343831] [10.1021/op500134e] |
7. Łazewska D, Kuder K, Ligneau X, Camelin JC, Schunack W, Stark H, Kieć-Kononowicz K. (2009) Diether derivatives of homo- or substituted piperidines as non-imidazole histamine H3 receptor ligands.. Bioorg Med Chem, 17 (8): (3037-42). [PMID:19329325] [10.1021/op500134e] |
8. Schwartz JC. (2011) The histamine H3 receptor: from discovery to clinical trials with pitolisant.. Br J Pharmacol, 163 (4): (713-21). [PMID:21615387] [10.1021/op500134e] |
9. Kollb-Sielecka M, Demolis P, Emmerich J, Markey G, Salmonson T, Haas M. (2017) The European Medicines Agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the Committee for Medicinal Products for Human Use.. Sleep Med, 33 (13): (125-129). [PMID:28449891] [10.1021/op500134e] |
10. Szakacs Z, Dauvilliers Y, Mikhaylov V, Poverennova I, Krylov S, Jankovic S, Sonka K, Lehert P, Lecomte I, Lecomte JM et al.. (2017) Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial.. Lancet Neurol, 16 (3): (200-207). [PMID:28129985] [10.1021/op500134e] |